

**SUVEN LIFE SCIENCES LTD**

Regd. Off: SDE Serene Chambers, 6th floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500034
STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2026 & UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026

Rs. In Lakhs

		STANDALONE				
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended	
		31/03/2026	31/12/2025	31/03/2025	31/03/2026	31/03/2025
		Refer note.8	Un-Audited	Refer note.8	Audited	Audited
1	Income					
	Revenue from operations	152.01	280.87	146.70	711.47	665.58
	Other Income	677.78	276.59	119.08	1,391.05	1,072.59
	Total income	829.79	557.46	265.78	2,102.52	1,738.17
2	Expenses					
	a) Cost of materials consumed	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	c) Employee benefits expense	582.89	626.84	606.61	2,414.94	2,082.49
	d) Finance costs	15.78	-	-	15.78	4.66
	e) Depreciation and amortisation expense	158.25	134.58	134.67	561.35	582.17
	f) R & D Expenses	810.19	590.96	848.73	2,797.24	3,043.16
	g) Other Expenses	379.41	552.25	182.78	1,799.49	733.67
	Total expenses	1,946.52	1,904.63	1,772.79	7,588.80	6,446.15
3	Profit before exceptional items & Tax (1-2)	(1,116.73)	(1,347.17)	(1,507.01)	(5,486.28)	(4,707.98)
4	Exceptional Items	-	-	-	-	-
5	Profit before Tax (3-4)	(1,116.73)	(1,347.17)	(1,507.01)	(5,486.28)	(4,707.98)
6	Tax Expenses					
	a) Current tax	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	-
7	Net Profit/ (Loss) for the period/year(3-4)	(1,116.73)	(1,347.17)	(1,507.01)	(5,486.28)	(4,707.98)
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	(22.45)	3.26	(4.64)	(22.19)	(5.99)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income / (Loss)	(22.45)	3.26	(4.64)	(22.19)	(5.99)
9	Total Comprehensive Income/ (Loss) for the period (5+6)	(1,139.18)	(1,343.91)	(1,511.65)	(5,508.47)	(4,713.97)
10	Paid-up equity share capital	2,637.20	2,274.74	2,180.74	2,637.20	2,180.74
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity		-	-	147,699.51	77,770.36
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :					
	a) Basic (Based on weighted average no.of shares)	(0.50)	(0.60)	(0.69)	(2.41)	(2.16)
	b) Diluted (Based on weighted average no.of shares)	(0.50)	(0.60)	(0.69)	(2.41)	(2.16)
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)



Sl. No.	PARTICULARS	CONSOLIDATED				
		For the Quarter Ended			For the year ended	
		31/03/2026 Refer note.8	31/12/2025 Un-Audited	31/03/2025 Refer note.8	31/03/2026 Audited	31/03/2025 Audited
1	Income					
	Revenue from operations	152.01	280.87	146.70	711.47	665.58
	Other Income	677.78	277.45	122.25	1,393.01	1,089.69
	Total income	829.79	558.32	268.95	2,104.48	1,755.27
2	Expenses					
	a) Cost of materials consumed	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	c) Employee benefits expense	582.89	626.84	606.61	2,414.94	2,082.49
	d) Finance costs	15.78	-	-	15.78	4.66
	e) Depreciation and amortisation expense	158.25	134.58	134.67	561.35	582.17
	f) R & D Expenses	4,233.12	9,404.72	3,732.50	24,818.81	14,396.18
	g) Other Expenses	399.30	584.36	189.66	1,928.01	764.27
	Total expenses	5,389.34	10,750.50	4,663.44	29,738.89	17,829.77
3	Profit before exceptional items & Tax (1-2)	(4,559.55)	(10,192.18)	(4,394.49)	(27,634.41)	(16,074.50)
4	Exceptional Items	-	-	-	-	-
5	Profit before Tax (3-4)	(4,559.55)	(10,192.18)	(4,394.49)	(27,634.41)	(16,074.50)
4	Tax Expenses					
	a) Current tax	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	-
5	Net Profit/ (Loss) for the period/year(5-6)	(4,559.55)	(10,192.18)	(4,394.49)	(27,634.41)	(16,074.50)
6	Other Comprehensive Income					
6.a	(i) Items that will not be reclassified to profit or loss	(22.45)	3.26	(4.64)	(22.19)	(5.99)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
6.b	(i) Items that will be reclassified to profit or loss	(24.21)	(78.39)	(52.34)	(96.20)	(52.34)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income / (Loss)	(46.66)	(75.13)	(56.98)	(118.39)	(58.33)
7	Total Comprehensive Income/ (Loss) for the period (5+6)	(4,606.21)	(10,267.31)	(4,451.47)	(27,752.80)	(16,132.83)
8	Paid-up equity share capital Face Value of the Share	2,637.20 Re.1.00	2,274.74 Re.1.00	2,180.74 Re.1.00	2,637.20 Re.1.00	2,180.74 Re.1.00
9	Other Equity	-	-	-	56,502.76	8,817.94
10	Earning Per Share (EPS) (Face value of Rs.1/- each) :					
	a) Basic (Based on weighted average no.of shares)	(2.02)	(4.55)	(2.02)	(12.13)	(7.37)
	b) Diluted(Based on weighted average no.of shares)	(2.02)	(4.55)	(2.02)	(12.13)	(7.37)
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)

SUVEN LIFE SCIENCES LTD

Regd. Off: SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500034



Statement of Assets & Liabilities

Rs. in Lakhs

Particulars	Standalone as at		Consolidated as at	
	31/03/2026	31/03/2025	31/03/2026	31/03/2025
A ASSETS				
1 Non-current assets				
(a) Property, Plant and Equipment	5,570.33	5,947.19	5,570.33	5,947.19
(b) Capital Work-in-Progress	359.60	0.97	359.60	0.97
(c) Other Intangible Assets	14.47	18.08	14.47	18.08
(d) Right of use Assets	1,714.74	-	1,714.74	-
(e) Financial Assets				
I. Investments	91,284.63	69,147.16	-	-
II. Other financial assets	87.50	4.86	87.50	4.86
(f) Other Non-current Assets	3.88	-	3.88	-
Total Non-Current assets	99,035.15	75,118.26	7,750.52	5,971.10
2 Current assets				
Inventories	10.20	23.75	10.20	23.75
(a) Financial Assets				
I. Investments in mutual funds	18,065.16	2,227.85	18,065.16	2,227.85
II. Trade Receivables	150.84	133.64	150.84	133.64
III. Cash and Cash equivalents	228.13	46.35	827.91	1,502.55
IV. Bank balances other than (III) above	32,917.70	1,950.00	32,917.70	2,270.08
V. Other financial assets	370.31	7.60	370.31	7.60
(b) Current Tax asset (net)	194.92	119.00	194.92	119.00
(c) Other current assets	2,133.84	1,262.76	2,133.84	1,262.76
Total Current assets	54,071.10	5,770.95	54,670.88	7,547.23
TOTAL - ASSETS	153,106.25	80,889.21	62,421.40	13,518.33
B EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share Capital	2,637.21	2,180.74	2,637.21	2,180.74
(b) Other Equity	147,699.51	77,770.36	56,502.76	8,817.94
Total Equity	150,336.72	79,951.10	59,139.97	10,998.68
2 LIABILITIES				
Non-current liabilities				
Provision for Employee benefits	191.74	171.05	191.74	171.05
Total non-current liabilities	191.74	171.05	191.74	171.05
Current liabilities				
(a) Financial Liabilities				
I. Lease Liabilities	1,669.42	-	1,669.42	-
II. Trade payables				
a) To Micro & Small Enterprises	36.33	38.42	36.33	38.42
b) Other than Micro & Small Enterprises	444.99	484.24	444.99	484.24
III. Other Financial Liabilities	52.09	20.07	563.99	1,601.61
(b) Provision Employee benefits	152.37	164.05	152.37	164.05
(c) Other Current liabilities	222.59	60.28	222.59	60.28
Total - Current liabilities	2,577.79	767.06	3,089.69	2,348.60
Total Liabilities	2,769.53	938.11	3,281.43	2,519.65
TOTAL - EQUITY AND LIABILITIES	153,106.25	80,889.21	62,421.40	13,518.33

Place : Hyderabad
Date : May 13, 2026

For SUVEN LIFE SCIENCES LTD

Venkat Jasti

VENKAT JASTI
Chairman & MD
DIN: 00278028



SUVEN LIFE SCIENCES LIMITED

Standalone Statement of Cash flows for the year ended 31st March, 2026

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
A. Cash flow from operating activities		
Profit/(Loss) before tax	(5,486.29)	(4,707.98)
Adjustments :		
Depreciation and amortisation expense	561.35	530.71
ESOP expenses	178.69	127.45
Interest Income	(422.92)	(557.32)
Finance Cost	15.78	4.66
Lease payment	(37.25)	-
interest on security deposit(116)	(0.75)	-
Foreign exchange loss/(profit)	24.23	-
Gain on Unrealised Current Investment	(953.70)	(497.56)
Operating profit before working capital changes	(6,120.86)	(5,100.04)
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	(17.20)	(5.05)
Inventories	13.55	47.10
Other non current assets	(3.88)	52.05
Other current assets	(871.08)	(186.01)
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	(65.56)	315.85
Long term provisions	20.69	36.45
Short term provision	(33.87)	46.40
Other financial liabilities	32.02	(15.77)
Other current liabilities	162.31	9.44
Cash generated from operating activities	(6,883.88)	(4,799.58)
Income taxes paid (net of refunds)	75.91	(60.51)
Net Cash flows from operating activities	(6,959.79)	(4,739.07)
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(508.34)	(3,727.58)
Other financial assets	(499.64)	209.22
Interest received	422.92	557.32
Changes in Investments	(22,137.47)	(11,435.81)
Sale/(purchase) of mutual funds	(14,883.61)	5,863.22
Bank balances not considered as cash and cash equivalents	(30,967.70)	12,954.71
Net cash flow from /(used in) investing activities	(68,573.84)	4,421.08
C. Cash flows from financing activities		
Proceeds from Issue of Equity shares and related reserves	75,715.41	-
Changes In Lease Liability	-	(70.97)
Finance Cost	-	(4.66)
Net cash flow from /(used In) financing activities	75,715.41	(75.63)
Net increase/(decrease) in cash and cash equivalents	181.78	(393.62)
Cash and cash equivalents as at the beginning of the year	46.35	439.97
Cash and cash equivalents at the end of the year	228.13	46.35
Cash and cash equivalents	228.13	46.35
Balances per statement of cash flows	228.13	46.35

For SUVEN LIFE SCIENCES LTD

Venkata Jasti

VENKAT JASTI
Chairman & MD
DIN: 00278028

Place : Hyderabad
Date : May 13, 2026



SUVEN LIFE SCIENCES LIMITED

Consolidated Statement of Cash flows for the year ended 31st March,2026

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars	For the year ended 31st March 2026	For the year ended 31st March 2025
A. Cash flow from operating activities		
Profit/(Loss) before tax	(27,634.41)	(16,074.50)
Adjustments :		
Depreciation and amortisation expense	561.35	530.71
ESOP expenses	178.69	127.45
Interest Income	(424.03)	(568.25)
Finance Cost	15.78	4.66
Lease payment	(37.25)	-
interest on security deposit(116)	(0.75)	
Foreign exchange loss/(profit)	24.23	
Gain on Unrealised Current Investment	(953.71)	(497.56)
Operating profit before working capital changes	(28,270.10)	(16,477.49)
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	(17.20)	(5.05)
Inventories	13.55	47.10
Other non current assets	(3.88)	52.05
Other current assets	(871.08)	(186.01)
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	(65.56)	315.85
Long term provisions	20.69	36.45
Short term provision	(33.87)	46.40
Other financial liabilities	(1,037.62)	690.29
Other current liabilities	162.31	9.44
Cash generated from operating activities	(30,102.76)	(15,470.97)
Income taxes paid (net of refunds)	75.91	(60.51)
Net Cash flows from operating activities	(30,178.67)	(15,410.46)
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(508.34)	(3,727.58)
Other financial assets	(499.64)	209.22
Interest received	424.03	568.25
Sale/(purchase) of mutual funds	(14,883.61)	5,863.22
Foreign currency translation reserve	(96.20)	(52.34)
Bank balances not considered as cash and cash equivalents	(30,647.62)	12,634.63
Net cash flow from /(used in) investing activities	(46,211.38)	15,495.40
C. Cash flows from financing activities		
Proceeds from Issue of Equity shares and related reserves	75,715.41	-
Changes In Lease Liability	-	(70.97)
Finance Cost	-	(4.66)
Net cash flow from /(used In) financing activities	75,715.41	(75.63)
Net increase/(decrease) in cash and cash equivalents	(674.64)	9.31
Cash and cash equivalents as at the beginning of the year	1,502.55	1,493.24
Cash and cash equivalents at the end of the year	827.91	1,502.55
Cash and cash equivalents	827.91	1,502.55
Balances per statement of cash flows	827.91	1,502.55

For SUVEN LIFE SCIENCES LTD

Venkata Jasti

VENKAT JASTI
Chairman & MD
DIN: 00278028

Place : Hyderabad
Date : May 13, 2026



NOTES:-

1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 13, 2026. The results for the year ended March 31, 2026 has been audited and for the quarter ended March 31, 2026 has been reviewed by our statutory auditors.

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc.

4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

5.1) The Company implemented SLSL Employee Stock Option Scheme 2020 ("ESOP") for eligible employees, which provides for the issuance of 10,00,000 options, each option convertible into one equity share. Out of these, 6,20,000 options were granted by the Nomination & Remuneration Committee on May 6, 2024.

5.2) ESOP: for the quarter ended March 31, 2026, the Company recognized an employee benefit expense (EBP) of Rs. 99.25 lakhs in accordance with Ind AS 102 – Share-based Payment. The cumulative EBP recognized as of March 2026 amounts to Rs.178.69 lakhs.

6) Preferential Issue: The Board of Directors of the Company approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025.

Each warrant is convertible into one equity share of face value ₹1/- at an exercise price of ₹134/- per share, within a period of 18 months from the date of allotment.

Out of the Issue proceeds of Rs.85,764 Lakhs, Rs.76433 Lakhs has been received and Rs. 9331Lakhs is yet to be received from warrant holders. During the period from July'25 to March'26 the Company has allotted 45432866 equity shares on a preferential basis upon conversion of equivalent number of fully paid warrants to six allottees, upon receipt of 100% of the warrant consideration amounting to Rs.60,880.04 lakhs.

Summary of Utilisation of Proceeds of Preferential issue as on 31.03.2026

Particulars	Rs.In lakhs
Amount Received through Preferential Issue	76,432.53
Less: Amount Utilised	26,068.64
Balance Amount	50,363.89

7) Impact of Labour Codes:

On November 21,2025, the government of India notified provisions of the new Labour Code (4 Labour codes) which consolidates 29 existing labour laws into a unified framework governing employee benefit. The labour codes, amongst other things, introduced changes including a uniform definition of wages and enhanced benefits relating to leave. The group has assessed the financial implications of these changes which had resulted in increase in gratuity liability arising out of past service cost by Rs.36.34 lakhs as at 31st Dec,2026 out of total Rs. 61.15 lakhs, for the year ended 31 March,2026.

The Group is in the process of evaluating the impact of other provisions of the Labour Codes, if any, and will recognise the same as and when such impact becomes reasonably ascertainable.

8) The figures for the current quarter and quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and March 31, 2025, respectively and published year to date figures upto 3rd quarter ended 31st December 2025 and 31st December 2024, respectively, regrouped as necessary.

Place : Hyderabad
Date: May 13, 2026



For SUVEN LIFE SCIENCES LTD

Venkata Jasti

VENKAT JASTI
Chairman & MD
DIN: 00278028